<p>Lyell Immunopharma, Inc.（納斯達克代碼：LYEL - 獲取免費報告）在週五的交易中股價下跌了 4.6%。該股票最低交易價為 29.71 美元，最後交易價為 29.35 美元。在交易中，共成交了 12,364 股，較平均交易量 74,330 股下降了 83%。該股票此前收盤價為 30.78 美元。</p>
<p>獲取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票研究分析師對 LYEL 股票發表了評論。HC Wainwright 將 Lyell Immunopharma 的股票評級從 “中性” 上調至 “買入”，並在 12 月 9 日的研究報告中將其目標價從 20.00 美元提高至 45.00 美元。Weiss Ratings 在 10 月 8 日的報告中重申了對 Lyell Immunopharma 股票的 “賣出（d-）” 評級。一位分析師給予該股票 “買入” 評級，另一位則給予 “賣出” 評級。根據 MarketBeat.com 的數據，Lyell Immunopharma 目前的平均評級為 “持有”，共識目標價為 45.00 美元。</p>
<p><strong>查看我們關於 Lyell Immunopharma 的最新研究報告</strong></p>
<h2>Lyell Immunopharma 股價下跌 10.8%</h2>
<p>該公司的 50 日移動平均線為 24.65 美元，200 日移動平均線為 16.53 美元。該公司的市值為 5.8314 億美元，市盈率為-1.19，貝塔值為-0.14。</p>
<p>Lyell Immunopharma（納斯達克代碼：LYEL - 獲取免費報告）最近於 11 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為-2.13 美元，超出分析師共識預期的-2.81 美元，超出幅度為 0.68 美元。該公司在本季度的收入為 0.02 百萬美元，而分析師預期為 0.01 百萬美元。Lyell Immunopharma 的股本回報率為-96.68%，淨利潤率為-794,292.69%。研究分析師預計 Lyell Immunopharma, Inc.在本年度將發佈-0.78 的每股收益。</p>
<h2>對 Lyell Immunopharma 的對沖基金看法</h2>
<p>大型投資者最近調整了對該股票的持有。Millennium Management LLC 在第三季度將其在 Lyell Immunopharma 的持股增加了 140.0%。Millennium Management LLC 目前擁有 125,361 股該公司的股票，價值 2,036,000 美元，此前在該期間內又購買了 73,132 股。Foresite Capital Management V LLC 在第三季度將其在 Lyell Immunopharma 的持股增加了 17.3%。Foresite Capital Management V LLC 目前擁有 477,078 股該公司的股票，價值 7,748,000 美元，此前在該期間內又收購了 70,426 股。ARCH Venture Management LLC 在第三季度將其在 Lyell Immunopharma 的持股增加了 51.5%。ARCH Venture Management LLC 目前擁有 2,759,072 股該公司的股票，價值 44,807,000 美元，此前在上個季度又收購了 938,438 股。Two Sigma Investments LP 在第三季度將其在 Lyell Immunopharma 的持股增加了 107.0%。Two Sigma Investments LP 目前擁有 20,827 股該公司的股票，價值 338,000 美元，此前在該期間內又收購了 10,768 股。最後，Takeda Pharmaceutical Co. Ltd.在第三季度將其在 Lyell Immunopharma 的持股增加了 33.3%。Takeda Pharmaceutical Co. Ltd.目前擁有 54,887 股該公司的股票，價值 891,000 美元，此前在上個季度又購買了 13,722 股。66.05% 的股票由機構投資者持有。</p>
<h2>Lyell Immunopharma 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Lyell Immunopharma 是一家臨牀階段的生物技術公司，專注於開發針對癌症的下一代 T 細胞療法。該公司利用一個結合了細胞療法、基因編輯和分子發現的專有平台，旨在克服治療實體腫瘤的關鍵障礙。該公司的方法集中在工程化 T 細胞，以增強其持久性、功能性和對免疫抑制腫瘤微環境的抵抗力。</p>
<p>該公司的產品線包括多個自體 T 細胞項目，旨在針對黑色素瘤、卵巢癌和胰腺癌等實體惡性腫瘤中的腫瘤相關抗原。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Lyell Immunopharma</li>
<li>在 2026 年 1 月 1 日之前購買這隻 2 美元的黃金股票</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>中國的轟動性揭露</li>
<li>請勿刪除，立即閲讀</li>
<li>BNZI 發佈創紀錄的第三季度收入 – 看看推動因素是什麼。</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Lyell Immunopharma 嗎？</h2>
<p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Lyell Immunopharma 並不在名單上。</p>
<p>雖然 Lyell Immunopharma 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LYEL

<p>Lyell Immunopharma（納斯達克代碼：LYEL）股價下跌 4.6%，至 29.35 美元，交易量較平均水平下降 83%。分析師意見不一，HC Wainwright 將該股票評級上調至 “買入”，並將目標價提高至 45 美元，而 Weiss Ratings 則維持 “賣出” 評級。該公司報告的季度每股收益為（2.13 美元），超出預期，但股本回報率為負的 96.68%。機構投資者持有 66.05% 的股份，公司專注於開發用於癌症的 T 細胞療法</p>

<p>Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) shares fell 4.6% during trading on Friday . The stock traded as low as $29.71 and last traded at $29.35. 12,364 shares changed hands during trading, a decline of 83% from the average session volume of 74,330 shares. The stock had previously closed at $30.78.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc.（納斯達克代碼：LYEL - 獲取免費報告）在週五的交易中股價下跌了 4.6%。該股票最低交易價為 29.71 美元，最後交易價為 29.35 美元。在交易中，共成交了 12,364 股，較平均交易量 74,330 股下降了 83%。該股票此前收盤價為 30.78 美元。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities research analysts have commented on LYEL shares. HC Wainwright raised shares of Lyell Immunopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and boosted their price target for the stock from $20.00 to $45.00 in a research report on Tuesday, December 9th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma presently has an average rating of &#34;Hold&#34; and a consensus target price of $45.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師對 LYEL 股票發表了評論。HC Wainwright 將 Lyell Immunopharma 的股票評級從 “中性” 上調至 “買入”，並在 12 月 9 日的研究報告中將其目標價從 20.00 美元提高至 45.00 美元。Weiss Ratings 在 10 月 8 日的報告中重申了對 Lyell Immunopharma 股票的 “賣出（d-）” 評級。一位分析師給予該股票 “買入” 評級，另一位則給予 “賣出” 評級。根據 MarketBeat.com 的數據，Lyell Immunopharma 目前的平均評級為 “持有”，共識目標價為 45.00 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Lyell Immunopharma</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Lyell Immunopharma 的最新研究報告</strong></p>
</div><h2>Lyell Immunopharma Stock Down 10.8%</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股價下跌 10.8%</h2>
</div><p>The business has a fifty day moving average of $24.65 and a 200 day moving average of $16.53. The firm has a market cap of $583.14 million, a P/E ratio of -1.19 and a beta of -0.14.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 24.65 美元，200 日移動平均線為 16.53 美元。該公司的市值為 5.8314 億美元，市盈率為-1.19，貝塔值為-0.14。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. Research analysts expect that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（納斯達克代碼：LYEL - 獲取免費報告）最近於 11 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為-2.13 美元，超出分析師共識預期的-2.81 美元，超出幅度為 0.68 美元。該公司在本季度的收入為 0.02 百萬美元，而分析師預期為 0.01 百萬美元。Lyell Immunopharma 的股本回報率為-96.68%，淨利潤率為-794,292.69%。研究分析師預計 Lyell Immunopharma, Inc.在本年度將發佈-0.78 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Lyell Immunopharma</h2>
<div class="lb-trans"><h2>對 Lyell Immunopharma 的對沖基金看法</h2>
</div><p>Large investors have recently modified their holdings of the stock. Millennium Management LLC boosted its holdings in shares of Lyell Immunopharma by 140.0% during the 3rd quarter. Millennium Management LLC now owns 125,361 shares of the company's stock worth $2,036,000 after buying an additional 73,132 shares during the period. Foresite Capital Management V LLC raised its holdings in Lyell Immunopharma by 17.3% in the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company's stock valued at $7,748,000 after acquiring an additional 70,426 shares during the period. ARCH Venture Management LLC lifted its position in Lyell Immunopharma by 51.5% during the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after acquiring an additional 938,438 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Lyell Immunopharma by 107.0% during the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company's stock worth $338,000 after acquiring an additional 10,768 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. grew its position in shares of Lyell Immunopharma by 33.3% in the third quarter. Takeda Pharmaceutical Co. Ltd. now owns 54,887 shares of the company's stock valued at $891,000 after purchasing an additional 13,722 shares during the last quarter. 66.05% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股票的持有。Millennium Management LLC 在第三季度將其在 Lyell Immunopharma 的持股增加了 140.0%。Millennium Management LLC 目前擁有 125,361 股該公司的股票，價值 2,036,000 美元，此前在該期間內又購買了 73,132 股。Foresite Capital Management V LLC 在第三季度將其在 Lyell Immunopharma 的持股增加了 17.3%。Foresite Capital Management V LLC 目前擁有 477,078 股該公司的股票，價值 7,748,000 美元，此前在該期間內又收購了 70,426 股。ARCH Venture Management LLC 在第三季度將其在 Lyell Immunopharma 的持股增加了 51.5%。ARCH Venture Management LLC 目前擁有 2,759,072 股該公司的股票，價值 44,807,000 美元，此前在上個季度又收購了 938,438 股。Two Sigma Investments LP 在第三季度將其在 Lyell Immunopharma 的持股增加了 107.0%。Two Sigma Investments LP 目前擁有 20,827 股該公司的股票，價值 338,000 美元，此前在該期間內又收購了 10,768 股。最後，Takeda Pharmaceutical Co. Ltd.在第三季度將其在 Lyell Immunopharma 的持股增加了 33.3%。Takeda Pharmaceutical Co. Ltd.目前擁有 54,887 股該公司的股票，價值 891,000 美元，此前在上個季度又購買了 13,722 股。66.05% 的股票由機構投資者持有。</p>
</div><h2>Lyell Immunopharma Company Profile</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.</p>
<div class="lb-trans"><p>Lyell Immunopharma 是一家臨牀階段的生物技術公司，專注於開發針對癌症的下一代 T 細胞療法。該公司利用一個結合了細胞療法、基因編輯和分子發現的專有平台，旨在克服治療實體腫瘤的關鍵障礙。該公司的方法集中在工程化 T 細胞，以增強其持久性、功能性和對免疫抑制腫瘤微環境的抵抗力。</p>
</div><p>The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.</p>
<div class="lb-trans"><p>該公司的產品線包括多個自體 T 細胞項目，旨在針對黑色素瘤、卵巢癌和胰腺癌等實體惡性腫瘤中的腫瘤相關抗原。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Bombshell Exposé on China Strikes</li>
<li>Do not delete, read immediately</li>
<li>BNZI Posts Record Q3 Revenue – See What’s Driving It.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Lyell Immunopharma</li>
<li>在 2026 年 1 月 1 日之前購買這隻 2 美元的黃金股票</li>
<li>警報：在 2026 年 1 月之前拋售這五隻股票！</li>
<li>中國的轟動性揭露</li>
<li>請勿刪除，立即閲讀</li>
<li>BNZI 發佈創紀錄的第三季度收入 – 看看推動因素是什麼。</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Lyell Immunopharma 嗎？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Lyell Immunopharma 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Lyell Immunopharma 並不在名單上。</p>
</div><p>While Lyell Immunopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lyell Immunopharma 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lyell Immunopharma (NASDAQ:LYEL) 股價下跌 4.6% - 以下是原因